John Hayslip

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 756 citations · Full text

Medicine, Oncology, Pharmacology +9

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou et al. · Journal of Clinical Oncology · 2019 · 701 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Safety and efficacy of navitoclax, a BCL-2 and BCL-X _L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

Sven de Vos, John P. Leonard, Jonathan W. Friedberg et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults

Anne McDonnell, Kristi L Lenz, Debra Frei‐Lahr et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2006 · 83 citations

Pharmacy, Oncology, Pharmacotherapy +13

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Daniel A. Pollyea, Jacqueline S. Garcia et al. · Blood · 2019 · 72 citations

Medicine, Pharmacotherapy, Chemotherapy +7